Di Marino Pietro, Mannetta Gianluca, Carella Consiglia, Grassadonia Antonino, Tinari Nicola, Natoli Clara, De Tursi Michele
Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy.
Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University, Chieti, Italy.
Int Med Case Rep J. 2020 Mar 16;13:89-93. doi: 10.2147/IMCRJ.S229080. eCollection 2020.
Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase () rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment.
We herein report the case of a 74-year-old woman who received crizotinib for metastatic -positive NSCLC. During the crizotinib treatment, complex renal cystic lesions with invasion of perirenal spaces and iliopsoas muscle appeared; two complex hepatic cysts were also observed. Almost all lesions disappeared after switching to alectinib, a second-generation inhibitor.
It would seem that alectinib is able to reduce in size and number hepatic and renal cysts caused by the crizotinib treatment. Nevertheless, further studies are needed to clarify the role of both crizotinib in the onset of renal and hepatic cysts and alectinib in their disappearance.
克唑替尼是首个被批准用于治疗间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌（NSCLC）的酪氨酸激酶抑制剂。在克唑替尼治疗期间，已观察到肾囊肿的发病率增加。
我们在此报告一例74岁女性，她因转移性ALK阳性NSCLC接受克唑替尼治疗。在克唑替尼治疗期间，出现了伴有肾周间隙和髂腰肌侵犯的复杂肾囊性病变；还观察到两个复杂肝囊肿。在换用第二代ALK抑制剂阿来替尼后，几乎所有病变均消失。
阿来替尼似乎能够减小克唑替尼治疗引起的肝囊肿和肾囊肿的大小并减少其数量。然而，需要进一步研究以阐明克唑替尼在肾囊肿和肝囊肿发生中的作用以及阿来替尼在其消失中的作用。
